KCKwai Wa Cheng

Kwai Wa Cheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kwai Wa Cheng has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Gordon B. Mills

    Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    3 shared publications
  • Roshan Agarwal

    Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    2 shared publications
  • Igor Jurisica

    Division of Signaling Biology, Ontario Cancer Institute, Toronto, ON, Canada

    1 shared publication
  • Joe W. Gray

    Lawrence Berkley National Laboratory, Berkeley, CA, USA

    1 shared publication
  • John P. Lahad

    Department of Molecular Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, Texas and

    1 shared publication
  • Joseph W. Gray

    Lawrence Berkeley National Laboratory, Berkeley, California

    1 shared publication

Latest Publications

  • Open Access

    Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress

    by Kwai Wa Cheng, Roshan Agarwal, Shreya Mitra, Ju‐Seog Lee, Mark Carey, Joe W. Gray, Gordon B. Mills

    Cancer cells are metabolically stressed during tumour progression due to limited tumour vascularity and resultant nutrient, growth factor and oxygen deficiency that can induce cell death and inhibit tumour growth. We demonstrate that Rab25, a small GTPase involved in endosomal recycling, that is genomically amplified in multiple tumour lineages, is a key regulator of cellular bioenergetics and autophagy. RAB25 enhanced survival during nutrient stress by preventing apoptosis and autophagy via binding and activating AKT leading to increased glucose uptake and improved cellular bioenergetics. Unexpectedly, Rab25 induced the accumulation of glycogen in epithelial cancer cells, a process not previously identified. Strikingly, an increase in basal ATP levels combined with AKT‐dependent increases in glucose uptake and glycogen storage allowed maintenance of ATP levels during bioenergetic stress. The clinical relevance of these findings was validated by the ability of a Rab25‐dependent expression profile enriched for bioenergetics targets to identify patients with a poor prognosis. Thus, Rab25 is an unexpected regulator of cellular bioenergetics implicated as a useful biomarker and potential therapeutic target.


  • Open Access

    The Emerging Role of the RAB25 Small GTPase in Cancer

    by Roshan Agarwal, Igor Jurisica, Gordon B. Mills, Kwai Wa Cheng

    RAB25, a member of the rat sarcoma (RAS) family of small GTPase, has been implicated in the pathophysiology of ovarian, breast and other cancers. Its role in endosomal transport and recycling of cell‐surface receptors and signaling proteins presents a novel paradigm for the disruption of cellular pathways and promotion of tumor development and aggressiveness. Variations in structure and post‐translational modifications control the localization of RAS superfamily proteins to specific subcellular compartments and recruitment of downstream effectors, allowing these small GTPases to function as sophisticated modulators of a complex and diverse range of cellular processes. Here, we review the link between RAB25 and tumor development and current knowledge regarding its possible roles in cancer.


  • Emerging Role of RAB GTPases in Cancer and Human Disease

    by Kwai W. Cheng, John P. Lahad, Joseph W. Gray, Gordon B. Mills

    Emerging evidence implicates alterations in the RAB small GTPases and their associated regulatory proteins and effectors in multiple human diseases including cancer. We have recently shown that RAB25, located at chromosome 1q22, is amplified at the DNA level and overexpressed at the RNA level in ovarian and breast cancer. These changes correlated with a worsened outcome in both diseases. In addition, enforced expression of RAB25 in both breast and ovarian cancer cells decreased apoptosis and increased proliferation and aggressiveness in vivo, potentially explaining the worsened prognosis. A better understanding of genetic alterations as well as the physiologic and pathophysiologic roles of RAB GTPases may open new opportunities for therapeutic intervention and better outcomes.